GLP1R and neurodegenerative disease: We further examine shared metabolic mechanisms between DE and neurodegenerative diseases such as alzheimer’s disease (AD) and treatment strategies for pathological metabolic reprogramming including GLP-1 receptor agonists, NAD+ boosters, and AMPK activators.